Találati lista | Tudóstér

001-es BibID:	BIBFORM013842
Első szerző:	Farkas Klaudia
Cím:	Red Blood Cell Distribution Width in Combination with Serological Markers can Help in the Differentiation between Crohn's Disease and Ulcerative Colitis / Klaudia Farkas, Mária Papp, Tibor Nyári, Ferenc Nagy, Zoltán Szepes, Tibor Wittmann, Tamás Molnár
Dátum:	2010
Megjegyzések:	Recent data suggest that red blood cell distribution width (RDW) could be a reliable marker indifferentiating Crohn's disease (CD) from ulcerative colitis (UC).Aim: Our study was to determine the sensitivity and specificity of RDW and serological markers for inflammatory boweldiseases (IBD), the risk for the diseases in case of abnormal RDW value and positive serological markersseparately and conjointly and to evaluate the efficacy of RDW in the differential diagnosis between IBD and irritablebowel syndrome (IBS). We also examined the influence of the drug treatments on the alteration of RDW values.Patients and methods: The clinical records of 98 CD, 81 UC, 26 IBS patients and 84 healthy controls were reviewed.Sensitivity, specificity and relative risk of RDW and ASCA IgA, ASCA IgG and anti-OmpC antibodies for CD and UCwere assessed. RDW values of IBS patients and IBD patients were also statistically compared.Results: RDW was significantly elevated in IBD patients compared to IBS patients. 92% specificity cutpoint at a RDWlevel of 13.4% was detected in both CD and UC independently of the disease activity. Significantly higher risk forCD was observed in case of combined assessment of abnormal RDW and positive ASCA IgA vs. the other serologicalmarkers or to separate determination of RDW.Conclusion: RDW could be a useful and inexpensive activity marker, which may help in the differential diagnosisbetween IBD and IBS and using in combination with ASCA IgA it shows a synergistic effect in the distinction of CDfrom UC.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Red blood cell distribution width Crohn's disease Open Access ulcerative colitis egyetemen (Magyarországon) készült közlemény
Megjelenés:	The Open Gastroenterology Journal. - 4 (2010), p. 1-4. -
További szerzők:	Papp Mária (1975-) (belgyógyász, gasztroenterológus) Nyári Tibor Nagy Ferenc (orvos Szeged) Szepes Zoltán Wittmann Tibor Molnár Tamás (orvos Szeged)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat Szerző által megadott URL
Borító:
Saját polcon:

001-es BibID:	BIBFORM043061
035-os BibID:	PMID:22935014
Első szerző:	Horváth Gábor (Semmelweis Kórház, Miskolc)
Cím:	Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? / Gábor Horváth, Klaudia Farkas, Renáta Hollósi, Ferenc Nagy, Zoltán Szepes, Mária Papp, Károly Palatka, Pál Miheller, László Lakatos, Tamás Szamosi, Tibor Nyári, Tibor Wittmann, Tamás Molnár
Dátum:	2012
ISSN:	0036-5521
Megjegyzések:	Inflammatory bowel diseases (IBD) have a huge impact on the patients' lives and require continuous medication and long-term medical follow-up. The Short Form Health Survey (SF-36) is a commonly used questionnaire measuring health-related quality of life (HRQOL). Our aim was to evaluate whether HRQOL influences medication adherence and vice versa in IBD patients, and to find relationships between demographic parameters, therapeutic modalities and non-adherence or HRQOL. PATIENTS AND METHODS: Five hundred ninety-two IBD patients treated at six Hungarian tertiary centers were enrolled. Patients completed the SF-36 questionnaire and a medication adherence report scale during their visits. The associations between demographic parameters, HRQOL, different kinds of therapies and non-adherence were analyzed. RESULTS: The most affected dimension was physical functioning and least affected were the social functions. About 42.7% of the patients revealed their HRQOL to be acceptable. About 74.6% of the patients believed that the prescribed medications actually improved their HRQOL. Diarrhea was the most common and most severe symptom during the course of the disease. Non-adherence was reported in 13.4% of the patients. 'Forgetting to take the medication' was the main reason for non-adherence in 67.6% of the cases. Medication adherence was significantly higher among nonsmoker patients, and also in the case of immunomodulator therapy. There was no association between the sum of HRQOL and different subscores and non-adherence. CONCLUSION: Inflammatory bowel disease is associated with low HRQOL, which is not affected by drug therapy. The impaired quality of life in IBD is mainly influenced by the disease itself.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Scandinavian Journal of Gastroenterology. - 47 : 11 (2012), p. 1298-1303. -
További szerzők:	Farkas Klaudia Hollósi Renáta Nagy Ferenc (orvos Szeged) Szepes Zoltán Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Miheller Pál Lakatos László (Veszprém) Szamosi Tamás Nyári Tibor Wittmann Tibor Molnár Tamás (orvos Szeged)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM028430
Első szerző:	Molnár Tamás (orvos Szeged)
Cím:	NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease / Molnar, T., Hofner, P., Nagy, F., Lakatos, P. L., Fischer, S., Lakatos, L., Kovacs, A., Altorjay, I., Papp, M., Palatka, K., Demeter, P., Tulassay, Z., Nyari, T., Miheller, P., Papp, J., Mandi, Y., Lonovics, J., The Hungarian IBD Study Group
Dátum:	2007
ISSN:	1590-8658
Megjegyzések:	NOD1/CARD4, a member of the pattern-recognition receptor family, is a perfect candidate as a susceptibility gene for Crohn's disease. Since only limited and conflicting data are available on G796A polymorphisms in inflammatory bowel disease patients, we set out to study the effect of this polymorphism on the susceptibility and course of Crohn's disease in the Hungarian population. METHODS: Four hundred thirty-four unrelated Crohn's disease patients (age at presentation: 28.6+/-9.6 years, female/male: 210/224, duration of Crohn's disease: 8.2+/-6.9 years) and 200 healthy subjects (blood donors) and 136 non-inflammatory bowel disease gastrointestinal controls with chronic gastritis were investigated. NOD1 G796A was detected by using polymerase chain reaction/restriction fragment length polymorphism. Detailed clinical phenotypes were determined by reviewing the medical charts. RESULTS: The frequencies of the variant alleles of NOD1 G796A differed significantly between the Crohn's disease patients and both healthy (GG 49.5% vs. 67%; AG 41.5% vs. 28%; and AA 9.0% vs. 5.2%; p<0.0001) and non-inflammatory bowel disease controls with chronic gastritis. Carriage of the single nucleotide polymorphism of NOD1 G796A proved to be a highly significant risk factor for Crohn's disease compared to both healthy (p<0.0001, OR: 2.1, 95% CI: 1.5-2.9) and non-inflammatory bowel disease controls with chronic gastritis (p=0.008). Significant associations were not found between the different genotypes and the demographic data on the patients or the clinical characteristics of Crohn's disease. The different polymorphisms of pattern-recognition receptors (e.g. NOD2/CARD15 SNP8, SNP12 and SNP13 mutations, the TLR4 D299G polymorphism and NOD1 G796A) did not reveal a mutual basis. CONCLUSIONS: Our results suggest that carriage of the NOD1 G796A mutation increases susceptibility for Crohn's disease in the Hungarian population.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Digestive And Liver Disease. - 39 : 12 (2007), p. 1064-1070. -
További szerzők:	Hofner P. Nagy Ferenc (orvos Szeged) Lakatos Péter (Semmelweis Egyetem) Fischer Simon Lakatos László (Veszprém) Kovács A. Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Demeter Pál Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Nyári Tibor Miheller Pál Papp János (Budapest) Mándi Yvette Lonovics János (Szeged) The Hungarian IBD Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM040343
Első szerző:	Molnár T. (orvos)
Cím:	Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy / Molnár T., Lakatos P. L., Farkas K., Nagy F., Szepes Z., Miheller P., Horváth G., Papp M., Palatka K., Nyári T., Bálint A., Lőrinczy K., Wittmann T.
Dátum:	2013
Megjegyzések:	BACKGROUND: Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. AIM: To assess the disease course and frequency of relapse of Crohn's disease (CD) following discontinuation of biological therapy, and to determine predictive factors for relapse. METHODS: One hundred twenty-one CD patients who had achieved clinical remission following 1 year of biological therapy and for whom biological therapy was then discontinued participated in this prospective observational study. Eighty-seven CD patients had received infliximab and 34 adalimumab. The definition of relapse was an increase of >100 points in CDAI to at least a CDAI of 150 points. RESULTS: Biological therapy was restarted within 1 year of treatment cessation in 45% of patients. Logistic regression analysis revealed that previous biological therapy (P = 0.011) and dose intensification during the 1-year course of biological therapy (P = 0.024) were associated with the need for and the time to the restarting of biological therapy. Smoking was observed to have an effect that was not statistically significant (P = 0.053). CONCLUSIONS: Biological therapy was restarted a median of 6 months after discontinuation in almost half of Crohn's disease patients in who had been in clinical remission following 1 year of biological therapy. These results suggest that, in the event of the presence of certain predictive factors, biological therapy should probably be continued for more than 1 year by most patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Alimentary Pharmacology and Therapeutics. - 37 : 2 (2013), p. 225-233. -
További szerzők:	Lakatos Péter (Semmelweis Egyetem) Farkas K. Nagy Ferenc (orvos Szeged) Szepes Zoltán Miheller Pál Horváth G. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Nyári Tibor Bálint Anita Lőrinczy K. Wittmann Tibor
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: